risankizumab
abbvie
['risan', 'crohn']
38. dr marla dubinsky: maintenance with risankizumab in crohn s among those who had delayed induction response (24 weeks) #marladubinsky #acg2022 clinical, endoscopic and composite endpoints looked reasonably good at wk 52 of maintenance 
I'm a Mayo specialist in evaluation and management of patients with ulcerative colitis and Crohn's disease. Tweets are mine. Retweet doesn't mean endorsement.